Free shipping on all orders over $ 500

Adalimumab

Cat. No. M6222

All AbMole products are for research use only, cannot be used for human consumption.

Adalimumab Structure
Synonym:

LU200134, D2E7, Anti-Human TNF-alpha

Size Price Availability Quantity
5mg USD 670  USD670 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Adalimumab blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).

In vivo: Adalimumab is safe and well tolerated. In healthy adults, the average absolute bioavailability of adalimumab 40 mg administered subcutaneously (s.c.) is 64%. Concentrations in the synovial fluid are 31-96% of those of the serum. Maximum plasma concentrations occur at 131 (± 56) h, and the mean half-life is ∼ 2 weeks (range, 10-20 days). Adalimumab treatment attenuates the Ovalbumin(OVA)-induced increase in serum IgE, TH2 and TH1 derived inflammatory cytokines (IL-4 and IFN-γ, respectively) in bronchoalveolar lavage (BAL) fluid, suppresses recruitment of inflammatory cells in BAL fluid and lung, and inhibits BAL fluid neutrophilia. It also ameliorates goblet cell metaplasia and bronchial fibrosis.

Protocol (for reference only)
Cell Experiment
Cell lines Caco-2 BBE cells
Preparation method T-84 and Caco-2 cells grown on transwell inserts were primed with IFN-γ (2.5 and 5 ng/ml, respectively) for 24 h followed by treatment with TNF-α (5 ng/ml), adalimumab (10 μg/ ml), or both.
Concentrations 10 μg/ ml
Incubation time 24 h
Animal Experiment
Animal models CD1 mice
Formulation PBS
Dosages 1 ml/100 g b.wt
Administration i.p.
Chemical Information
CAS Number 331731-18-1
Storage Store at -20°C or -70°C. Avoid multiple freeze-thaws.
References

[1] Jacks SM, et al. J Am Acad Dermatol. Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab.

[2] Fischer A, et al. Am J Physiol Gastrointest Liver Physiol. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.

Related TNF Receptor Products
Ozekibart

Ozekibart is an anti-TNFRSF10B monoclonal antibody.

TAPI-0 

TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM.

Semapimod tetrahydrochloride

Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6.

BMS-566394

BMS-566394 is a potent, exceptionally selective inhibitor of TNF-α converting enzyme (TACE).

APVO603

APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

  Catalog
Abmole Inhibitor Catalog




Keywords: Adalimumab, LU200134, D2E7, Anti-Human TNF-alpha supplier, TNF Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.